Structure Therapeutics (GPCR) Rallying on Obesity Drug Data [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
study as well as top-line data from a capsule-to-tablet PK study on its obesity candidate, GSBR-1290, on Jun 3. Both studies met their primary and secondary endpoints. GSBR-1290 is a highly selective oral GLP-1 receptor agonist, being evaluated in multiple mid-stage studies for treating healthy overweight or obese individuals. The capsule-to-tablet PK study was designed to evaluate the tolerability, safety and pharmacokinetics of a new tablet formulation of GSBR-1290 in the given patient population. Data from the phase IIa obesity study showed that treatment with GSBR-1290 led to a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks. Notably, 67% of the patients who were treated with GSBR-1290 experienced a =6% reduction in their body weight, while 33% of the patients achieved a = 10% reduction in their body weight compared to none for placebo at 12 weeks of treatment. Data from the capsule-to-tablet PK study showe
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report InvestigatesPR Newswire
- Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report InvestigatesPR Newswire
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary SharesGlobeNewswire
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its price target raised by analysts at BMO Capital Markets from $83.00 to $100.00. They now have an "outperform" rating on the stock.MarketBeat
GPCR
Sec Filings
- 6/14/24 - Form 4
- 6/13/24 - Form 3
- 6/12/24 - Form 4
- GPCR's page on the SEC website